Published in Drug Week, January 27th, 2006
The fast track programs of the FDA are designed to facilitate development and expedited review of investigational drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Compounds designated with fast track status are eligible for accelerated FDA review and early submission of portions of the associated biologics license application for marketing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.